AstraZeneca discontinues CAPItello-280 Phase III trial of Truqap in metastatic prostate cancer
Why we think this is neutral
The RNS announcement is a clinical trial update, which is not one of the mandatory news types that require detailed analysis. Therefore, a neutral sentiment score is appropriate.
Key Points
- AstraZeneca is discontinuing the CAPItello-280 Phase III trial of Truqap in metastatic castration-resistant prostate cancer
- The decision is based on the recommendation of the Independent Data Monitoring Committee following a pre-specified interim analysis
- The Truqap combination was unlikely to meet the dual primary endpoints of radiographic progression-free survival and overall survival
Summary
AstraZeneca is discontinuing the CAPItello-280 Phase III trial evaluating the efficacy and safety of Truqap (capivasertib) in combination with docetaxel and androgen-deprivation therapy (ADT) in patients with metastatic castration-resistant prostate cancer. This decision is based on the recommendation of the Independent Data Monitoring Committee following a pre-specified interim analysis, which concluded that the Truqap combination was unlikely to meet the dual primary endpoints of radiographic progression-free survival and overall survival. The safety profile was consistent with previous trials.